Journal
IMMUNOTHERAPY
Volume 2, Issue 3, Pages 305-327Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/IMT.10.17
Keywords
aberrant O-linked glycosylation; cancer; episialin; immunotherapy; MUC1; polymorphic epithelial mucin
Categories
Funding
- Cancer Research UK (61 Lincoln's Inn Fields, London WC2A 3PX, UK) [1089464]
- King's College London (The Strand, London WC2R 2LS, UK)
Ask authors/readers for more resources
The overexpression and aberrant glycosylation of MUC1 is associated with a wide variety of cancers, making it an ideal target for immunotherapeutic strategies. This review highlights the main avenues of research in this field, focusing on adenocarcinomas, from the preclinical to clinical; the problems and possible solutions associated with each approach; and speculates on the direction of MUC1 immunotherapeutic research over the next 5-10 years.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
